Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to understand oncology financial market dynamics and wisely build investment portfolios comprised of company stocks that fight Pancreatic Cancer.
The Global Pancreatic Cancer Treatment Market was valued at USD 2.87 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2030.
The pancreatic cancer treatment market has been categorized into exocrine and endocrine segments. For exocrine, the pancreas loses the ability to produce and supply digestive enzymes to the small intestine, resulting in indigestion. The majorly increasing prevalence of chronic pancreatitis and an increase in the consumption of sugar and alcohol induce the treatment for the exocrine pancreatic segment. The exocrine segment dominated with a share of 84.2% in 2023. The endocrine segment is expected to grow at the fastest CAGR of 15.0% during the forecast period.
The pancreatic cancer treatment market has been categorized into chemotherapy, radiation therapy, and others. Chemotherapy is the dominant segment, with a global share of 57.9% in 2023. Radiation therapy is anticipated to witness a significant CAGR over the forecast period.
North America dominated the pancreatic cancer treatment market, with a global share of 37.7% in 2023, due to high healthcare spending, favorable policies, an increase in pancreatic cancer incidences, and major pharmaceutical players. Europe was the second most dominant player in 2023. The UK has been the most important region in Europe due to the presence of one-third of the geriatric population in the region. The Asia-Pacific region accounted for a significant share of the pancreatic cancer treatment market in 2023.
For additional information on Pancreatic Cancer, please review the video by Mechanisms in Medicine Inc.